Clinical trials: Diabetes Mellitus II
Type II Diabetes
Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes
The purpose of this study is to assess the safety and feasibility of the Fractyl Duodenal Remodeling System for the treatment of patients with poorly controlled Type 2 Diabetes.
- Trial name
- NCT01927562
- Testing
- Fractyl Duodenal Remodeling System
- Where
- Chile
- Volunteers
- 57 people
- Sponsor
- Fractyl Health Inc.
Type II Diabetes Mellitus
A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease
Evaluation the change of patients' glycosylated hemoglobin (HbA1c) after 12 weeks diet control
- Trial name
- NCT02446054
- Testing
- Musashino T2DM diet
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Celio Technology Inc.
Type 1 Diabetes Mellitus, Type 1 Diabetes
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
- Trial name
- NCT00690066
- Testing
- PROCHYMAL®
- Where
- 20 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mesoblast, Inc.
Type II Diabetes
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
According to the objective, the trial is constituted by two study groups: one is food effect assessment group, and another is multiple dose pharmacokinetic assessment group.
- Trial name
- NCT05120219
- Testing
- FDC tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type II
GOLO Open-Label Pilot 1
The objective of this open-label pilot study is to evaluate the effect of the commercially available GOLO for Life (GFL) weight management program on body weight in a type 2 diabetic patient population after approximately 3…
- Trial name
- NCT03478202
- Testing
- GOLO RELEASE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Golo
Liver Dysfunction
Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
The objective of the study is to compare the pharmacokinetics profiles and safety of Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral dose of Evogliptin
- Trial name
- NCT02754219
- Testing
- Evogliptin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes, Bladder Cancer
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes
To assess the potential association between pioglitazone and bladder cancer compared with non-pioglitazone users among patients with type 2 diabetes mellitus.
- Trial name
- NCT01637935
- Testing
- Pioglitazone
- Volunteers
- 193,099 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Eze/Simva Switch Study in Diabetics (0653A-807)
A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.
- Trial name
- NCT00541697
- Testing
- MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks
- Volunteers
- 648 people
- Sponsor
- Organon and Co
Diabetic Kidney Disease, IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to…
- Trial name
- NCT05687890
- Testing
- SC0062 low dose, SC0062 medium dose, SC0062 high dose
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Diabetic Foot Ulcer
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.
- Trial name
- NCT06383013
- Testing
- BB-101
- Where
- 5 sites in Taiwan
- Volunteers
- 96 people
- Sponsor
- Blue Blood Biotech Corp.
Diabetes Mellitus, Type 1, Autoimmune Diseases
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2…
- Conditions
- Diabetes Mellitus, Type 1, Autoimmune Diseases, Prevention
- Trial name
- NCT05683990
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Diamyd Medical AB
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetic Foot Ulcer
TWB-103 for Treating Lower Limb Ulcers on Patients With DM
Primary Objective: To assess the safety profile of TWB-103 administered to subjects with diabetic lower limb ulcers Secondary Objective: To explore the efficacy of TWB-103 administered to subjects with diabetic lower limb ulcers
- Trial name
- NCT03624023
- Testing
- TWB-103
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Transwell Biotech Co., Ltd.
Diabetes Mellitus
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-619, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00763347
- Testing
- SYR-619, Alogliptin
- Volunteers
- 82 people
- Sponsor
- Takeda
Type II Diabetes Mellitus
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
The objectives of this study is to determine the safety profiles, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following single ascending doses in healthy adult subjects.
- Trial name
- NCT01952535
- Testing
- HMS5552
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hua Medicine Limited
it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either
Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy…
- Conditions
- it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either, Because the Body Does Not Produce Enough Insulin,, or Because Cells do Not Respond to the Insulin That
- Trial name
- NCT01226537
- Testing
- Taurine
- Volunteers
- 20 people
- Sponsor
- Hamad Medical Corporation
Diabetes Mellitus
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.
The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months of pioglitazone, once daily…
- Trial name
- NCT00449553
- Testing
- Pioglitazone and sulphonylurea, Pioglitazone and metformin
- Where
- 4 sites in Denmark, Iceland and 2 more
- Volunteers
- 326 people
- Sponsor
- Takeda
Diabetic Nephropathy
Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy.
- Trial name
- NCT02205372
- Testing
- MT-3995
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes
Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking metformin to treat their diabetes. In addition, this initial trial will evaluate insulin resistance (HOMA-IR index), HgbA1c levels, glycated…
- Trial name
- NCT00506298
- Testing
- bezafibrate + diflunisal
- Where
- 18 sites in Canada
- Volunteers
- 150 people
- Sponsor
- Zalicus
Diabetes Mellitus Type I, Diabetes Mellitus Type II
Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4
This is a multi-center, non-randomized, and interventional study in which subjects will use the Integrated sensor and infusion set with MiniLink Transmitter and the Medtronic Paradigm® VEO™ insulin pump (Sensor augmented pump)…
- Trial name
- NCT01775059
- Testing
- Integrated sensor and infusion set.
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Medtronic Diabetes R&D Denmark